Erdafitinib 4 mg (Balversa) is a medication used for the treatment of urothelial carcinoma, a type of bladder cancer, particularly in patients with FGFR3 or FGFR2 genetic alterations. It is marketed under the brand name Balversa and is a tyrosine kinase inhibitor (TKI) that works by targeting specific mutations in the fibroblast growth factor receptors (FGFRs), which are involved in cancer cell growth and survival.

Erdafitinib 4 mg (Balversa)

Product Overview: Erdafitinib 4 mg (Balversa) is an oral medication that is used to treat metastatic urothelial carcinoma (a type of bladder cancer) in patients who have specific mutations in the fibroblast growth factor receptors (FGFRs), specifically FGFR2 or FGFR3. It works by inhibiting the activity of FGFR, which is involved in the growth and survival of cancer cells. By blocking these receptors, Erdafitinib helps slow the growth of cancer cells and may improve survival in patients with specific genetic alterations.

Key Benefits:

• Targeted therapy for metastatic urothelial carcinoma with FGFR mutations (FGFR2 or FGFR3).
• Improves overall survival in patients whose cancer has progressed after platinum-based chemotherapy.
• Oral administration, making it convenient for patients to manage their treatment at home.
• Well-tolerated with a manageable side effect profile when monitored properly.

Indications:

• Metastatic Urothelial Carcinoma: Erdafitinib is used to treat locally advanced or metastatic urothelial carcinoma in adult patients with FGFR2 or FGFR3 mutations who have previously received platinum-based chemotherapy.
• It is indicated for patients whose tumors have shown alterations in FGFR2 or FGFR3, as detected by an FDA-approved test.

Dosage:

• The recommended dose for Erdafitinib 4 mg (Balversa) is 8 mg once daily, which may be adjusted by your healthcare provider based on how you respond to the medication.
• Dose modifications may be required in case of adverse reactions, and your healthcare provider may adjust the dose to 4 mg or 6 mg per day depending on tolerability.
• Erdafitinib should be taken with or without food.
• Patients are typically monitored closely for side effects, particularly ocular issues (eye-related effects), and doses may be adjusted if necessary.

Precautions:

• Ocular Toxicity: Erdafitinib can cause eye problems such as retinal detachment, macular edema, and visual disturbances. Regular eye exams are required before starting treatment and periodically during therapy.
• Hyperphosphatemia: Elevated phosphorus levels in the blood can occur with Erdafitinib and should be monitored regularly. High phosphate levels can lead to complications like heart problems and should be managed appropriately.
• Liver function: Liver enzyme levels should be regularly monitored, as Erdafitinib can affect liver function in some patients.
• Pregnancy: Erdafitinib may harm an unborn baby, and it is not recommended during pregnancy. Patients should use effective contraception during treatment and for a specified period after treatment.
• Kidney function: Patients with severe kidney impairment may need dose adjustments and close monitoring.

Common Side Effects:

• Eye-related issues (e.g., blurred vision, dry eyes, eye pain, visual disturbances, macular edema)
• Fatigue
• Nausea
• Stomatitis (inflammation of the mouth)
• Hyperphosphatemia (high phosphate levels)
• Diarrhea
• Anemia (low red blood cells)
• Rash

Packaging:

• Erdafitinib 4 mg (Balversa) is available in a convenient oral tablet form. The tablets are typically packaged in [insert packaging type] to ensure secure storage and ease of access for the patient.

Important Notes:

• Regular monitoring: Patients taking Erdafitinib should undergo regular eye exams, blood tests to monitor phosphate levels, and liver function tests during treatment.
• Adherence: It is important to take Erdafitinib exactly as prescribed, and not to adjust the dose without consulting your healthcare provider.
• Storage: Store Erdafitinib in a cool, dry place, away from moisture and direct sunlight, and out of reach of children.